|
1
|
Dahiya S, Murphy ES, Chao ST, Stevens GH,
Peereboom DM and Ahluwalia MS: Recurrent or refractory primary
central nervous lymphoma: Therapeutic considerations. Expert Rev
Anticancer Ther. 13:1109–1119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kleinschmidt-DeMasters BK, Damek DM,
Lillehei KO, Dogan A and Giannini C: Epstein Barr virus-associated
primary CNS lymphomas in elderly patients on immunosuppressive
medications. J Neuropathol Exp Neurol. 67:1103–1111. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Löw S and Batchelor TT: Primary central
nervous system lymphoma. Semin Neurol. 38:86–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zorofchian S, El-Achi H, Yan Y, Esquenazi
Y and Ballester LY: Characterization of genomic alterations in
primary central nervous system lymphomas. J Neurooncol.
140:509–517. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu X, Li Z, Shen J, Chan MT and Wu WK:
Role of microRNAs in primary central nervous system lymphomas. Cell
Prolif. 49:147–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Royer-Perron L, Hoang-Xuan K and Alentorn
A: Primary central nervous system lymphoma: Time for diagnostic
biomarkers and biotherapies? Curr Opin Neurol. 30:669–676. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zheng J, Xu J, Ma S, Sun X, Geng M and
Wang L: Clinicopathological study of gene rearrangement and
microRNA expression of primary central nervous system diffuse large
B-cell lymphomas. Int J Clin Exp Pathol. 6:2048–2055.
2013.PubMed/NCBI
|
|
8
|
Musilova K and Mraz M: MicroRNAs in B-cell
lymphomas: How a complex biology gets more complex. Leukemia.
29:1004–1017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Crooks V, Waller S, Smith T and Hahn TJ:
The use of the karnofsky performance scale in determining outcomes
and risk in geriatric outpatients. J Gerontol. 46:M139–M144. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Villano JL, Koshy M, Shaikh H, Dolecek TA
and McCarthy BJ: Age, gender, and racial differences in incidence
and survival in primary CNS lymphoma. Br J Cancer. 105:1414–1418.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu X, Nerisho S, Dastidar P, Ryymin P,
Järvenpää R, Pertovaara H, Eskola H and Kellokumpu-Lehtinen PL:
Comparison of different MRI sequences in lesion detection and early
response evaluation of diffuse large B-cell lymphoma - a whole-body
MRI and diffusion-weighted imaging study. NMR Biomed. 26:1186–1194.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ichiki A, Carreras J, Miyaoka M, Kikuti
YY, Jibiki T, Tazume K, Watanabe S, Sasao T, Obayashi Y, Onizuka M,
et al: Clinicopathological analysis of 320 cases of diffuse large
B-cell lymphoma using the hans classifier. J Clin Exp Hematop.
57:54–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu W, Sun M, Zou GM and Chen J: MicroRNA
and cancer: Current status and prospective. Int J Cancer.
120:953–960. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Han J, Cui Y, Fan K and Zhou X:
Circulating microRNA-21 as noninvasive predictive biomarker for
response in cancer immunotherapy. Med Hypotheses. 81:41–43. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ivo D'Urso P, Fernando D'Urso O, Damiano
Gianfreda C, Mezzolla V, Storelli C and Marsigliante S: miR-15b and
miR-21 as circulating biomarkers for diagnosis of glioma. Curr
Genomics. 16:304–311. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roth P, Keller A, Hoheisel JD, Codo P,
Bauer AS, Backes C, Leidinger P, Meese E, Thiel E, Korfel A and
Weller M: Differentially regulated miRNAs as prognostic biomarkers
in the blood of primary CNS lymphoma patients. Eur J Cancer.
51:382–390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao HY, Wang W, Luo XG, Jiang YF, He X, Xu
P, Chen X and Li XY: Screening of prognostic risk microRNAs for
acute myeloid leukemia. Hematology. 23:747–755. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Greither T, Grochola LF, Udelnow A,
Lautenschlager C, Würl P and Taubert H: Elevated expression of
microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated
with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baraniskin A, Kuhnhenn J, Schlegel U, Chan
A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A,
Schmiegel W, et al: Identification of microRNAs in the
cerebrospinal fluid as marker for primary diffuse large B-cell
lymphoma of the central nervous system. Blood. 117:3140–3146. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baraniskin A, Kuhnhenn J, Schlegel U,
Maghnouj A, Zöllner H, Schmiegel W, Hahn S and Schroers R:
Identification of microRNAs in the cerebrospinal fluid as biomarker
for the diagnosis of glioma. Neuro Oncol. 14:29–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baraniskin A, Kuhnhenn J, Schlegel U,
Schmiegel W, Hahn S and Schroers R: MicroRNAs in cerebrospinal
fluid as biomarker for disease course monitoring in primary central
nervous system lymphoma. J Neurooncol. 109:239–244. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Conti A, Aguennouz M, La Torre D,
Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germanò A,
Vita G and Tomasello F: miR-21 and 221 upregulation and miR-181b
downregulation in human grade II–IV astrocytic tumors. J
Neurooncol. 93:325–332. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei D, Wan Q, Li L, Jin H, Liu Y, Wang Y
and Zhang G: MicroRNAs as potential biomarkers for diagnosing
cancers of central nervous system: A meta-analysis. Mol Neurobiol.
51:1452–1461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lawrie CH, Gal S, Dunlop HM, Pushkaran B,
Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J,
Wainscoat JS, et al: Detection of elevated levels of
tumour-associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mao X, Sun Y and Tang J: Serum miR-21 is a
diagnostic and prognostic marker of primary central nervous system
lymphoma. Neurol Sci. 35:233–238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rubenstein JL, Gupta NK, Mannis GN,
Lamarre AK and Treseler P: How I treat CNS lymphomas. Blood.
122:2318–2330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y and Sarkar FH: MicroRNA targeted
therapeutic approach for pancreatic cancer. Int J Biol Sci.
12:326–337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gasparini P, Cascione L, Landi L, Carasi
S, Lovat F, Tibaldi C, Alì G, D'Incecco A, Minuti G, Chella A, et
al: microRNA classifiers are powerful diagnostic/prognostic tools
in ALK-, EGFR-, and KRAS-driven lung cancers. Proc Natl Acad Sci
USA. 112:14924–14929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Winther M, Alsner J, Tramm T, Baeksgaard
L, Holtved E and Nordsmark M: Evaluation of miR-21 and miR-375 as
prognostic biomarkers in esophageal cancer. Acta Oncol.
54:1582–1591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Koutova L, Sterbova M, Pazourkova E,
Pospisilova S, Svobodova I, Horinek A, Lysak D and Korabecna M: The
impact of standard chemotherapy on miRNA signature in plasma in AML
patients. Leuk Res. 39:1389–1395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang CC, Carnevale J and Rubenstein JL:
Progress in central nervous system Lymphomas. Br J Haematol.
166:311–325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chakraborty C, Doss CG, Sarin R, Hsu MJ
and Agoramoorthy G: Can the chemotherapeutic agents perform
anticancer activity through miRNA expression regulation? Proposing
a new hypothesis [corrected]. Protoplasma. 252:1603–1610. 2015.
View Article : Google Scholar : PubMed/NCBI
|
